News
XOMA
40.17
-1.29%
-0.58
*News On XOMA Royalty Corp. (XOMA) Now Under LGND
Dow Jones · 07/14 21:08
Press Release: XOMA Royalty Announces Closing of Its Acquisition by Ligand
Dow Jones · 07/14 13:01
Weekly Report: what happened at XOMA last week (0706-0710)?
Weekly Report · 07/13 09:37
Weekly Report: what happened at XOMA last week (0629-0703)?
Weekly Report · 07/06 09:39
Weekly Report: what happened at XOMA last week (0622-0626)?
Weekly Report · 06/29 09:37
Weekly Report: what happened at XOMA last week (0615-0619)?
Weekly Report · 06/22 09:41
Weekly Report: what happened at XOMA last week (0608-0612)?
Weekly Report · 06/15 09:42
XOMA Details Merger Timeline and Preferred Share Redemption
TipRanks · 06/12 23:53
XOMA Corp - 8.375% DP PFD B declares $0.5234 dividend
Seeking Alpha · 06/12 20:31
XOMA Preferred Shares Series A declares $0.539 dividend
Seeking Alpha · 06/12 20:14
Press Release: XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date
Dow Jones · 06/12 20:05
XOMA Royalty Sets July Vote on $39-per-Share Ligand Takeover and Reorganization
TipRanks · 06/10 23:02
Weekly Report: what happened at XOMA last week (0601-0605)?
Weekly Report · 06/08 09:39
Weekly Report: what happened at XOMA last week (0525-0529)?
Weekly Report · 06/01 09:42
Weekly Report: what happened at XOMA last week (0518-0522)?
Weekly Report · 05/25 09:43
Xoma downgraded to Hold from Buy at Benchmark
TipRanks · 05/22 15:47
XOMA Royalty Advances Merger Plans and Governance Changes
TipRanks · 05/22 10:35
Can XOMA's Late-Stage Pipeline Finally Justify the Royalty Model?
Barchart · 05/18 16:03
XOMA Royalty amends merger agreement with Ligand Pharmaceuticals
TipRanks · 05/18 14:08
Weekly Report: what happened at XOMA last week (0511-0515)?
Weekly Report · 05/18 09:43
More
Webull provides a variety of real-time XOMA stock news. You can receive the latest news about XOMA Royalty Corporation through multiple platforms. This information may help you make smarter investment decisions.
About XOMA
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.